Impact of exercise training on dipeptidyl peptidase 4 and insulin-like growth factor binding protein 1 in patients with coronary artery disease: Relationship to nitric oxide response
Thomas RJ, King M, Lui K, Oldridge N, Piña IL, AACVPR/ACCF/AHA SJ. American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Cardiology Foundation; American Heart Association Task Force on Performance Measures (Writing Committee to Develop Clinical Performance Measures for Cardiac Rehabilitation. In: the American Physical Therapy Association, the Canadian Association of Cardiac Rehabilitation, the Clinical Exercise Physiology Association, the European Association for Cardiovascular Prevention and Rehabilitation, the Inter-American Heart Foundation, the National Association of Clinical Nurse Specialists, the Preventive Cardiovascular Nurses Association, and the Society of Thoracic Surgeons J Am CollCardiol. 2010. p. 1159–67.
2.
Rajwani A, Ezzat V, Smith J, Yuldasheva NY, Duncan ER, Gage M, et al. Increasing Circulating IGFBP1 Levels Improves Insulin Sensitivity, Promotes Nitric Oxide Production, Lowers Blood Pressure, and Protects Against Atherosclerosis. Diabetes. 2012;61(4):915–24.
3.
Borai A, Livingstone C, Ghayour-Mobarhan M, Abuosa A, Shafi S, Mehta S, et al. Serum insulin-like growth factor binding protein-1 (IGFBP-1) phosphorylation status in subjects with and without ischaemic heart disease. Atherosclerosis. 2010;208(2):593–8.
4.
Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, et al. High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. American Heart Journal. 2008;155(6):1006–12.
5.
Kinugawa S. Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovascular Research. 1999;43(1):157–64.
6.
Cittadini A, Ishiguro Y, Strömer H, Spindler M, Moses AC, Clark R, et al. Insulin-like Growth Factor-1 but Not Growth Hormone Augments Mammalian Myocardial Contractility by Sensitizing the Myofilament to Ca 2+ Through a Wortmannin-Sensitive Pathway. Circulation Research. 1998;83(1):50–9.
7.
Li B, Setoguchi M, Wang X, Andreoli AM, Leri A, Malhotra A, et al. Insulin-Like Growth Factor-1 Attenuates the Detrimental Impact of Nonocclusive Coronary Artery Constriction on the Heart. Circulation Research. 1999;84(9):1007–19.
8.
Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, et al. Cardiac Stem Cell and Myocyte Aging, Heart Failure, and Insulin-Like Growth Factor-1 Overexpression. Circulation Research. 2004;94(4):514–24.
9.
Haqqani AS, Do SK, Birnboim HC. The role of a formaldehyde dehydrogenase–glutathione pathway in protein S-nitrosation in mammalian cells. Nitric Oxide. 2003;9(3):172–81.
10.
Navarro-Gonzálvez JA, García-Benayas C, Arenas J. Semiautomated Measurement of Nitrate in Biological Fluids. Clinical Chemistry. 1998;44(3):679–81.
11.
Minamiyama Y, Takemura S, Inoue M. Effect of Thiol Status on Nitric Oxide Metabolism in the Circulation. Archives of Biochemistry and Biophysics. 1997;341(1):186–92.
12.
van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. International Journal of Cardiology. 2017;232:294–303.
13.
Lavie CJ, Arena R, Swift DL, Johannsen NM, Sui X, Lee D chul, et al. Exercise and the Cardiovascular System. Circulation Research. 2015;117(2):207–19.
14.
Nazarenko MS, Puzyrev VP, Lebedev IN. Methylation profiling of human atherosclerotic plaques. MolBiol (Mosk. 2011;45:610–6.
15.
Alves AJ, Viana JL, Cavalcante SL, Oliveira NL, Duarte JA, Mota J, et al. Physical activity in primary and secondary prevention of cardiovascular disease: Overview updated. World Journal of Cardiology. 2016;8(10):575.
16.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren WMM, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine. 2012;19(4):403–88.
17.
Heath GW, Parra DC, Sarmiento OL, Andersen LB, Owen N, Goenka S, et al. Evidence-based intervention in physical activity: lessons from around the world. The Lancet. 2012;380(9838):272–81.
18.
Malin SK, Huang H, Mulya A, Kashyap SR, Kirwan JP. Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome. Peptides. 2013;47:142–7.
19.
Reinehr T, Roth CL, Enriori PJ, Masur K. Changes of Dipeptidyl Peptidase IV (DPP-IV) in Obese Children with Weight Loss: Relationships to Peptide YY, Pancreatic Peptide, and Insulin Sensitivity. Journal of Pediatric Endocrinology and Metabolism. 2010;23(1–2).
20.
Majorczyk M, Smoląg D. Effects of physical activity on IGF 1 and IGFBP levels in the context of civilization diseases prevention. Rocz Panstw Zakl Hig. 2016;67:105–11.
21.
Liew CF, Wise SD, Yeo KP, Lee KO. Insulin-Like Growth Factor Binding Protein-1 Is Independently Affected by Ethnicity, Insulin Sensitivity, and Leptin in Healthy, Glucose-Tolerant Young Men. The Journal of Clinical Endocrinology & Metabolism. 2005;90(3):1483–8.
22.
Maddux BA, Chan A, Mandarino LJ, Goldfine ID, De Filippis EA. IGF-Binding Protein-1 Levels Are Related to Insulin-Mediated Glucose Disposal and Are a Potential Serum Marker of Insulin Resistance. Diabetes Care. 2006;29(7):1535–7.
23.
Lewitt MS, Hilding A, Östenson CG, Efendic S, Brismar K, Hall K. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia. 2008;51(7):1135–45.
24.
Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. The Lancet. 2002;359(9319):1740–5.
25.
Janszky I, Hallqvist J, Ljung R, Hammar N. Insulin-like growth factor binding protein-1 is a long-term predictor of heart failure in survivors of a first acute myocardial infarction and population controls. International Journal of Cardiology. 2010;138(1):50–5.
26.
Wallander M, Norhammar A, Malmberg K, Öhrvik J, Rydén L, Brismar K. IGF Binding Protein 1 Predicts Cardiovascular Morbidity and Mortality in Patients With Acute Myocardial Infarction and Type 2 Diabetes. Diabetes Care. 2007;30(9):2343–8.
27.
Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, et al. Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus. Hepatogastroenterology. 2011;58(112).
28.
Griffin KL, Woodman CR, Price EM, Laughlin MH, Parker JL. Endothelium-Mediated Relaxation of Porcine Collateral-Dependent Arterioles Is Improved by Exercise Training. Circulation. 2001;104(12):1393–8.
29.
Cossette S, Frasure-Smith N, Lespérance F. Clinical Implications of a Reduction in Psychological Distress on Cardiac Prognosis in Patients Participating in a Psychosocial Intervention Program. Psychosomatic Medicine. 2001;63(2):257–66.
30.
Marchionni N, Fattirolli F, Fumagalli S, Oldridge N, Del Lungo F, Morosi L, et al. Improved Exercise Tolerance and Quality of Life With Cardiac Rehabilitation of Older Patients After Myocardial Infarction. Circulation. 2003;107(17):2201–6.
31.
Walther C, Gielen S, Hambrecht R. The Effect of Exercise Training on Endothelial Function in Cardiovascular Disease in Humans. Exercise and Sport Sciences Reviews. 2004;129–34.
32.
Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, et al. Percutaneous Coronary Angioplasty Compared With Exercise Training in Patients With Stable Coronary Artery Disease. Circulation. 2004;109(11):1371–8.
33.
Landmesser U, Hornig B, Drexler H. Endothelial Function. Circulation. 2004;109(21_suppl_1).
34.
TRITTO I, AMBROSIO G. The multi-faceted behavior of nitric oxide in vascular “inflammation”: catchy terminology or true phenomenon? Cardiovascular Research. 2004;63(1):1–4.
35.
Chen X. Biochemical Properties of Recombinant Prolyl Dipeptidases DPP-IV and DPP8. Advances in Experimental Medicine and Biology. p. 27–32.
36.
BARNETT A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. International Journal of Clinical Practice. 60(11):1454–70.
37.
Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease. Circulation: Cardiovascular Imaging. 2010;3(2):195–201.
38.
Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, et al. Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Improves Endothelial Dysfunction in Association With Its Anti-Inflammatory Effects in Patients With Coronary Artery Disease and Uncontrolled Diabetes. Circulation Journal. 2013;77(5):1337–44.
39.
Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, et al. The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone. The Scientific World Journal. 2012;2012:1–8.
40.
Krijnen PAJ, Hahn NE, Kholová I, Baylan U, Sipkens JA, Alphen FP, et al. Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic Research in Cardiology. 2012;107(1).
41.
VelijaAsimi Z, Izetbegovic S, Karamehic J, Coric J, Panjeta M, MacicDzankovic A, et al. The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes. Medical Archives. 2013;67(5):365.
42.
Mulvihill EE, Varin EM, Gladanac B, Campbell JE, Ussher JR, Baggio LL, et al. Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis. Cell Metabolism. 2017;25(1):152–65.
43.
Sharma A, Paliwal G, Upadhyay N, Tiwari A. RETRACTED ARTICLE: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. Journal of Diabetes & Metabolic Disorders. 2015;14(1).
44.
Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome. 2016;8(1).
45.
Sigal RJ, Kenny GP, Boulé NG, Wells GA, Prud’homme D, Fortier M, et al. Effects of Aerobic Training, Resistance Training, or Both on Glycemic Control in Type 2 Diabetes. Annals of Internal Medicine. 2007;147(6):357–69.
46.
Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends in Endocrinology & Metabolism. 2009;20(4):153–62.
47.
Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. The Lancet. 2002;359(9319):1740–5.
48.
Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001;44(3):333–9.
49.
Janssen JAMJL, Stolk RP, Pols HAP, Grobbee DE, Lamberts SWJ. Serum Total IGF-I, Free IGF-I, and IGFBP-1 Levels in an Elderly Population. Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18(2):277–82.
50.
Nolte AA, Movin M, Lundin H, Salminen H. IGFBP-1 predicts all-cause mortality in elderly women independently of IGF-I. Growth Hormone & IGF Research. 2015;25(6):281–5.
51.
Chisalita SI, Dahlström U, Arnqvist HJ, Alehagen U. Proinsulin and IGFBP-1 predicts mortality in an elderly population. International Journal of Cardiology. 2014;174(2):260–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
